XDH and Hypertension: To the best of our knowledge, this sub-analysis of the BEYOND-UA trial is the first study to show that the selective XOR inhibitor topiroxostat improved arterial stiffness parameters (CAVI and baPWV) in hyperuricemic patients with hypertension and liver dysfunction.